Contribute Try STAT+ Today

The tiny mouse embryos were off to a promising start, many of them progressing from a one-cell fertilized egg to two-, four-, and even eight-cell blobs resembling raspberries-to-be. As the eager scientists carefully tracked their development (in lab dishes), many of the embryos formed characteristic structures called pronuclei that housed the DNA of egg and sperm, following the normal developmental script. And they began turning specific genes on or off, again as happens during normal gestation, seemingly on their way to becoming mouse fetuses and, eventually, newborns.

But then the embryos hit a wall. Not a single one divided past the eight-cell stage. And that is cause for either relief or disappointment, depending where you stand on one of the wilder ideas in reproductive medicine: These embryos came from eggs produced from stem cells, which are easily created from skin and other cells. Their apparent inability to develop into baby mice suggests that using, say, skin cells to create baby-to-be eggs in humans is further off than some dystopian scenarios have envisioned.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.